GLP-1 Medications Explained: What They Are and What's Coming

• Groups the GLP-1 class by how the medicines actually differ, not by brand
• Explains GLP-1 against DPP-4 inhibitors, and single against dual agonists
• Covers side effects, injection site bruising and how to report a reaction
• Sets out the real UK approval route behind every "new weight loss drug" headline

GLP-1 medicines have gone from a specialist diabetes treatment to something discussed in every workplace kitchen in about three years. The information has not kept up. Most of what people read is either a product page or a headline about a medicine that is years away from a UK patient.

This page does something different. It explains what the class actually is, groups the medicines by how they genuinely differ from one another, and sets out what happens before any new one becomes available here. It also covers the practical questions people ask after they start, including the bruise that appears at the injection site and whether it matters.

Every medicine discussed here is prescription only in the UK. Nothing below is a recommendation to use any specific treatment, and treatment suitability depends on an individual clinical assessment.

Key things to know

• GLP-1 receptor agonists mimic a natural hormone released after eating, which is why the MHRA describes them as helping people feel fuller.
• All GLP-1 are prescription-only medicine in the UK and can only be prescribed by a healthcare professional.
• GLP-1 medicines include single-receptor agonists and oral or injectable formulations. Some newer medicines, such as tirzepatide, also target the GIP receptor. Triple-agonist medicines remain under investigation and should not be presented as established UK treatment options.
• Gastrointestinal side effects are common. Pancreatitis is a less common but serious risk that the MHRA asks prescribers to discuss.
• The MHRA advises that these medicines should never be bought from unregulated sellers such as beauty salons or social media.

What is a GLP-1?

GLP-1 stands for glucagon-like peptide-1, a naturally occurring hormone your gut releases after you eat. A GLP-1 medicine is a manufactured molecule that acts on the same receptor as that hormone, which is why these are properly called GLP-1 receptor agonists. Some GLP-1 receptor agonists are recommended in NICE guidance for managing type 2 diabetes or obesity, depending on the medicine, its licensed indication and the person's clinical circumstances.

The MHRA describes them as medicines that help people feel fuller by mimicking a natural hormone released after eating. That phrase is worth holding on to, because it explains both what they do and why appetite is the thing that changes. GLP-1 agonists work alongside a reduced calorie diet and lifestyle changes as part of a treatment plan to help manage overweight and obesity safely and effectively.

How do GLP-1 medications work?

Three effects, working together.

They act on appetite signalling in the brain, which reduces hunger and the sense of needing to keep eating. They slow the rate at which the stomach empties, so food stays put for longer and fullness lasts. And they increase insulin release in response to a meal while reducing glucagon, which is why the class was developed for type 2 diabetes before its weight effects were licensed.

These effects can reduce hunger and make it easier for some people to eat less. Weight regulation is influenced by biological, behavioural, environmental and other factors, so obesity should not be reduced to a question of willpower.

What do "mimetic" and "receptor agonist" mean?

An agonist is a molecule that switches a receptor on, in the way the body's own hormone would. A mimetic is the same idea in plainer language: something that imitates a natural substance. GLP-1 mimetic and GLP-1 receptor agonist describe the same thing, and you will see both used.

The medicines are not identical to the human hormone. They are modified so they survive far longer in the body, which is what allows once daily or once weekly dosing rather than the minutes the natural hormone lasts.

The GLP-1 family, grouped by how they differ

Rather than listing product names, it is more useful to understand the two axes on which these medicines actually differ: how many hormone receptors they act on, and how you take them.

Format is the axis most people care about, because it decides whether treatment means a weekly injection or something you swallow. GLP-1 treatment taken as a daily tablet exists for people who will not inject, and that is a legitimate factor for a prescriber to weigh rather than a lesser option.

Single receptor agonists

These act on the GLP-1 receptor alone and were the first to arrive. Within this group the practical differences are how often you take them and whether they are injected or swallowed, rather than differences in mechanism.

Dual agonist weight loss medication

Targeting both the GLP-1 and GIP receptors can improve blood glucose control and produce substantial weight loss with tirzepatide. The size of the effect depends on the medicine, dose, indication and individual response.

Which of these is appropriate for any individual is a clinical decision rather than a ranking. Your prescriber will determine the appropriate treatment based on your history, other medicines, other conditions and how you tolerate what you start.

GLP-1 medicines versus DPP-4 inhibitors

Both act on the same hormone system, but from opposite ends, and the difference matters for weight.

A GLP-1 receptor agonist supplies a long lasting molecule that switches the receptor on directly. DPP-4 inhibitors increase the availability of the body's own incretin hormones, whereas GLP-1 receptor agonists directly activate the GLP-1 receptor. GLP-1 receptor agonists generally have a greater effect on weight, while DPP-4 inhibitors are usually weight neutral.

The short version is that a DPP-4 inhibitor raises your natural hormone level modestly, while a GLP-1 receptor agonist produces a much larger and longer signal. That is why one class is used for weight management and the other is not.

Injection or tablet

Most GLP-1 medicines are given by subcutaneous injection, meaning into the fat layer just under the skin, using a pre-filled pen with a very short fine needle. Depending on the medicine, that is either daily or weekly.

Oral GLP-1 tablets

Oral forms exist and are taken once a day. Getting a peptide to survive the stomach is the hard part, which is why oral formulations arrive later and come with specific instructions about how and when to take them.

Oral GLP-1 medicines are generally taken daily, and some require specific instructions about fasting, food, water or other medicines. Follow the patient information leaflet for the exact product prescribed. If you miss a dose, follow its missed-dose instructions rather than doubling the next dose.

Follow the patient information leaflet exactly, and if a dose is missed, never take two to make up for it.

Neither format is the right one in general. A weekly injection means remembering one thing a week, which suits some people, while a daily tablet suits people who would rather not handle needles at all. Both are prescription only and both need the same assessment first.

Weight loss medication options in the UK

UK medicines used for weight management include GLP-1 receptor agonists, the dual GLP-1/GIP receptor agonist tirzepatide, and orlistat, which reduces the absorption of dietary fat. These medicines work differently and have different eligibility criteria, precautions and prescribing pathways. Not every medicine in these groups is authorised for weight management.

The most common side effects include feeling sick and gastrointestinal discomfort, but there is a low risk of acute pancreatitis and other adverse effects. Patients with kidney disease or high blood pressure should discuss the risks with their healthcare provider, as these conditions can affect treatment choices and monitoring.

GLP-1 medications, including semaglutide tablets and extended release formulations, are designed for once weekly injection or daily oral intake, depending on the brand names and patient needs. Some GLP-1 medicines have demonstrated cardiovascular benefits in specific patient populations, but these benefits cannot be assumed for every medicine in the class or every patient. Their authorised indications and supporting evidence differ. Treatment decisions should take account of the medicine's approved use and the person's medical history.

Which weight loss medication is right for you?

There is no ranking, and any page that gives you one is selling something. The appropriate medicine depends on your BMI and related health conditions, other medicines you take, other diagnoses, whether injections are acceptable to you, and how you respond to what you start.

NICE positions medicines as something considered after dietary, activity and behavioural approaches have been started and evaluated, rather than instead of them. The decision itself belongs with a prescriber, and results vary between individuals.

Medicines that are not licensed in the UK

Phentermine with topiramate is a combination used for weight management in some countries outside the UK, and it appears in UK searches because of that. It is not a licensed weight management treatment here.

If you are offered it, or any medicine without a UK marketing authorisation, the answer is no, and the reason is straightforward. A medicine without a UK licence has not been assessed by the MHRA for use here, there is no UK approved patient information, and nobody is accountable for its quality. That is not a technicality. It is the whole basis on which you can trust what is in the box.

The practical alternative is to look at the weight loss medicines a UK prescriber can consider, all of which hold a UK licence and come with approved patient information.

Are new weight loss drugs coming to the UK?

Yes, the pipeline is active, and the honest answer to "when" is that nobody outside the process can tell you. What is more useful is understanding the route, because it explains why headlines and availability are years apart.

How a new medicine actually reaches a UK patient

1. Clinical trials. Phase 1, 2 and 3 studies establish safety, dose and effect. Phase 3 is the large one and usually takes years.
2. MHRA review. The manufacturer applies for a UK marketing authorisation. The MHRA assesses the full data package and decides whether the medicine can be sold in the UK, for which conditions and with what warnings.
3. The licence defines everything. What it is approved to treat, who it is approved for and what the patient information says are all fixed at this point.
4. NICE appraisal. NICE separately assesses clinical and cost effectiveness for use in the health system.
5. Availability. Promising clinical trial results do not mean a medicine is ready for UK patients. It must meet the relevant regulatory requirements, and its eventual availability depends on factors such as approval, prescribing arrangements and supply. Some products may never receive authorisation.

Why "new GLP-1 coming out" headlines run ahead of reality

Most reports of a promising new weight loss medicine describe trial results, not an approval. A medicine can produce striking phase 3 data and still be two or more years from a UK prescription, or never arrive at all if the regulator is not satisfied.

There is also a specific risk attached to this gap. Where demand exists and supply does not, unlicensed and falsified products appear. The MHRA is explicit that GLP-1 medicines should not be bought from unregulated sellers such as beauty salons or via social media, or from anywhere without a prior consultation with a healthcare professional.

GLP-1 side effects

Common side effects

The most common are gastrointestinal. The MHRA describes nausea, vomiting and diarrhoea among the most common effects, and notes that gastrointestinal side effects may affect more than 1 in 10 patients.

Constipation, indigestion, reduced appetite, burping and tiredness are also frequently reported. Most of these are most noticeable early on and after any dose change, and they often ease.

Less common but serious

Very rare reports have linked semaglutide treatment to non-arteritic anterior ischaemic optic neuropathy (NAION), a serious condition that can affect vision. Sudden changes in vision require urgent medical assessment.

Severe, persistent abdominal pain, particularly pain that goes through to your back and comes with vomiting, needs urgent medical attention rather than a wait and see approach. A serious eye condition affecting vision has also been linked, in very rare reports, to one medicine in this class.

If you take insulin or a sulfonylurea alongside a GLP-1 medicine, low blood glucose becomes a risk. When a GLP-1 medicine is used with insulin or a sulfonylurea, the risk of hypoglycaemia may increase. Follow the prescribed hypoglycaemia management plan and seek urgent help for severe symptoms, confusion, loss of consciousness or symptoms that do not improve.

Reporting a side effect

Anyone who suspects they have had an adverse reaction to a GLP-1 medicine should report it through the MHRA Yellow Card scheme. You do not need to be certain the medicine caused it, and you do not need a healthcare professional to do it for you.

This matters more than it sounds for a newer class of medicine. Yellow Card reports are how rare effects are detected after licensing, which is when most of them are found.

Injection site reactions and bruising

Why does bruising happen on a GLP-1 injection?

A small bruise can occur after a GLP-1 injection if the needle damages a tiny blood vessel beneath the skin. A minor bruise alone does not necessarily mean the medicine was administered incorrectly or that the dose failed.

Redness, mild itching, a small lump or slight tenderness at the site are also frequently reported and generally settle within a few days. People who bruise easily anyway, or who take medicines that affect clotting, will see it more often.

Reducing injection site reactions

• Rotate the site each time rather than reusing the same spot, which gives tissue time to recover.
• Follow the product's storage and administration instructions. If the patient information leaflet permits it, allowing the medicine to reach the recommended temperature before injecting may improve comfort.
• Use a new needle every time, because a reused needle is blunt and causes more trauma.
• Do not rub the area afterwards. Light pressure with clean tissue is enough.
• Avoid injecting into an area that is already bruised, tender, scarred or broken.
• Dispose of needles in a sharps bin, never in household waste.

When an injection site reaction needs advice

Most do not. Contact a healthcare professional if the area becomes hot, increasingly painful, swollen or starts to spread; if there is pus or discharge; if you develop a fever; if a lump persists for weeks; or if you have signs of an allergic reaction such as a widespread rash, swelling of the face, lips or throat, or difficulty breathing. That last group needs emergency care.

Getting these medicines safely

Every GLP-1 medicine is prescription only, which means a legitimate supply always involves an assessment by a healthcare professional first. The MHRA is direct that these medicines should not be bought without prior consultation.

A legitimate UK prescribing service should conduct an appropriate clinical assessment, review your medical history and current medicines, verify relevant information, and arrange prescribing and supply through appropriately authorised professionals and pharmacies. You should receive the required patient information for your medicine. Check the relevant professional registers if you are unsure about a service.

You can start a weight loss consultation online and a UK registered prescriber will assess whether treatment is appropriate for you. Treatment suitability depends on an individual clinical assessment.

Medical Disclaimer

This article is general information about a class of medicines and is not medical advice. It does not recommend any specific treatment, contains no dosing instructions and is not a substitute for a consultation with a qualified healthcare professional. All GLP-1 medicines are prescription only and should be used only under the supervision of an appropriately qualified prescriber.

Treatment suitability depends on an individual clinical assessment, and results vary between individuals. Seek urgent medical attention for severe or persistent abdominal pain, repeated vomiting, sudden vision changes, or signs of an allergic reaction such as swelling of the face, lips or throat or difficulty breathing. Suspected side effects can be reported through the MHRA Yellow Card scheme.